Compare Summit Therapeutics Inc (SMMT) vs Sony Group Corp (SONY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs Sony Group Corp — how do they compare? Summit Therapeutics Inc trades at $17.47 (market cap $13.71B), while Sony Group Corp trades at $24.2 (market cap $136.87B). The key difference: Sony Group Corp is far larger — about 10× Summit Therapeutics Inc's market cap, and Sony Group Corp pays a 0.66% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Summit Therapeutics Inc for 16 Days and Sony Group Corp for 96 Days on average.
| SMMT | SONY | |
|---|---|---|
Market Cap | $13.71B | $136.87B |
Volume | 6,173,057 | 5,364,503 |
Sector | Health | Technology |
52-Week High | $26.38 | $30.26 |
52-Week Low | $12.43 | $19.32 |
Typical Hold Time | 16 Days | 96 Days |
Enterprise Value | $13.04B | $134.77B |
Dividend Yield | — | 0.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.
The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.
Sony (SONY) trades at $24.24, up 3.06% with a bullish technical signal from moving averages. The company reported strong Q4 2025 and Q2 2026 earnings beats but missed Q1 2026 expectations. Revenue remains stable around $12.96T with improved net income of $1.14T in 2025, though 2026 projections show a net loss. Analyst consensus is strongly bullish with 11 buy ratings and no sell recommendations. Recent news highlights Sony's content strength and legal actions against AI copyright infringement.
Sony presents a mixed outlook with strong entertainment assets and improving cash flow offset by projected 2026 profitability challenges. The stock's current valuation metrics appear reasonable, but investors should monitor execution risks in content monetization and competitive pressures in the entertainment sector. The bullish analyst sentiment and technical momentum suggest near-term upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About Sony Group Corp
Sony Group is a conglomerate with consumer electronics roots, which not only designs, develops, produces, and sells electronic equipment and devices, but also is engaged in content businesses, such as console and mobile games, music, and movies. Sony is a global top company of CMOS image sensors, game consoles, professional broadcasting cameras, and music publishing, and is one of the top players on digital cameras, wireless earphones, recorded music, movies, and so on. Sony's business portfolio is well diversified with six major business segments. The company fully consolidated Sony Financial in September 2020, which provides life and non-life insurance, banking, and other financial services.
Read more on SONY →
